Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

Compare

340 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZNTL Analyst Ratings

Moderate Buy

4 Buy

2 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Zentalis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZNTL Stock 12 Month Forecast

Average Price Target

$6.60

▲(368.09% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Zentalis Pharmaceuticals in the last 3 months. The average price target is $6.60 with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 368.09% change from the last price of $1.41.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,2.1538461538461537,2.8076923076923075,3.4615384615384617,4.115384615384615,4.769230769230769,5.423076923076923,6.076923076923077,6.730769230769231,7.384615384615385,8.038461538461538,8.692307692307693,9.346153846153847,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.8923076923076922,2.2846153846153845,2.676923076923077,3.069230769230769,3.4615384615384617,3.853846153846154,4.246153846153846,4.638461538461538,5.030769230769231,5.423076923076923,5.815384615384615,6.207692307692308,{"y":6.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.6923076923076923,1.8846153846153846,2.076923076923077,2.269230769230769,2.4615384615384617,2.653846153846154,2.8461538461538463,3.0384615384615383,3.230769230769231,3.4230769230769234,3.6153846153846154,3.807692307692308,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$6.60

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Ulz

Morgan Stanley

$8→$4

Hold

183.69%

Upside

Reiterated

11/12/25

Zentalis price target lowered to $4 from $8 at Morgan StanleyZentalis price target lowered to $4 from $8 at Morgan Stanley

Andres Y. Maldonado

H.C. Wainwright

$10

Buy

609.22%

Upside

Reiterated

11/11/25

Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. WainwrightHence, we reiterate our Buy rating and $10PT.

Matthew Biegler

Oppenheimer

Buy

538.30%

Upside

Reiterated

11/11/25

Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

Hold

183.69%

Upside

Reiterated

11/11/25

Wedbush Remains a Hold on Zentalis Pharmaceuticals (ZNTL)Reiterating Hold and our $4 PT.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/10/25

Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

Buy

325.53%

Upside

Reiterated

11/10/25

Guggenheim Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Andrew Berens

Leerink Partners

Hold

254.61%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Their Hold Rating for Zentalis Pharmaceuticals (ZNTL)

Derek Archila

Wells Fargo

$6→$5

Hold

254.61%

Upside

Reiterated

08/06/25

Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism

Akash Tewari

Jefferies

$6→$2.5

Hold

77.30%

Upside

Reiterated

01/29/25

Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.50 at JefferiesJefferies analyst Akash Tewari lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.50 (from $6.00) while maintaining a Hold rating.

Eliana Merle

UBS

$5→$2.2

Hold

56.03%

Upside

Reiterated

01/28/25

Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.20 at UBSUBS analyst Eliana Merle lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.20 (from $5.00) while maintaining a Neutral rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Ulz

Morgan Stanley

$8→$4

Hold

183.69%

Upside

Reiterated

11/12/25

Zentalis price target lowered to $4 from $8 at Morgan StanleyZentalis price target lowered to $4 from $8 at Morgan Stanley

Andres Y. Maldonado

H.C. Wainwright

$10

Buy

609.22%

Upside

Reiterated

11/11/25

Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. WainwrightHence, we reiterate our Buy rating and $10PT.

Matthew Biegler

Oppenheimer

Buy

538.30%

Upside

Reiterated

11/11/25

Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

Hold

183.69%

Upside

Reiterated

11/11/25

Wedbush Remains a Hold on Zentalis Pharmaceuticals (ZNTL)Reiterating Hold and our $4 PT.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/10/25

Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

Buy

325.53%

Upside

Reiterated

11/10/25

Guggenheim Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Andrew Berens

Leerink Partners

Hold

254.61%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Their Hold Rating for Zentalis Pharmaceuticals (ZNTL)

Derek Archila

Wells Fargo

$6→$5

Hold

254.61%

Upside

Reiterated

08/06/25

Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism

Akash Tewari

Jefferies

$6→$2.5

Hold

77.30%

Upside

Reiterated

01/29/25

Eliana Merle

UBS

$5→$2.2

Hold

56.03%

Upside

Reiterated

01/28/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zentalis Pharmaceuticals

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+0.91%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +0.91% per trade.

3 Months

xxx

Success Rate

9/19 ratings generated profit

Average Return

-7.46%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of -7.46% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

3/9 ratings generated profit

Average Return

-34.23%

reiterated a buy rating last month

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -34.23% per trade.

2 Years

xxx

Success Rate

3/9 ratings generated profit

Average Return

-46.00%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -46.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZNTL Analyst Recommendation Trends

Rating

Jun 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZNTL has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ZNTL average Analyst price target in the past 3 months is 6.60.

Each month's total comprises the sum of three months' worth of ratings.

ZNTL Financial Forecast

ZNTL Earnings Forecast

Next quarter’s earnings estimate for ZNTL is -$0.43 with a range of -$0.53 to -$0.31. The previous quarter’s EPS was -$0.37. ZNTL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ZNTL has Performed in-line its overall industry.

ZNTL Sales Forecast

Next quarter’s sales forecast for ZNTL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ZNTL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ZNTL has Performed in-line its overall industry.

ZNTL Stock Forecast FAQ

What is ZNTL’s average 12-month price target, according to analysts?

Based on analyst ratings, Zentalis Pharmaceuticals’s 12-month average price target is 6.60.

What is ZNTL’s upside potential, based on the analysts’ average price target?

Zentalis Pharmaceuticals has 368.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZNTL a Buy, Sell or Hold?

Zentalis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.

What is Zentalis Pharmaceuticals’s price target?

The average price target for Zentalis Pharmaceuticals is 6.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 368.09% Increase from the current price of $1.41.

What do analysts say about Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ZNTL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

ZNTL Analyst Ratings

ZNTL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zentalis Pharmaceuticals

ZNTL Analyst Recommendation Trends

ZNTL Financial Forecast

ZNTL Earnings Forecast

ZNTL Sales Forecast

ZNTL Stock Forecast FAQ

Detailed List of Analyst Forecasts